Geron Corp. (GERN), a biopharmaceutical company, on Tuesday said it received a U.S. patent with broad claims to cardiomyocytes derived from human embryonic stem cells.
Menlo Park, California-based Geron said the patent providing broad coverage of hESC-derived cardiomyocytes for cell therapy and drug screening applications is valid up to April 2025. The company's GRNCM1 program is developing hESC-derived cardiomyocytes for the treatment of heart disease.
Cardiomyocytes derived from human embryonic stem (hES) cells are spontaneously contracting cells, useful in restoring heart function after myocardial infarction or in heart failure.
Thomas Okarma, President and Chief Executive Officer said, "We are also exploring the potential to use these functional human cardiomyocytes in various drug discovery applications, as a tool enabling the development of safer and more effective drugs."
Geron's portfolio of owned and in-licensed patents relating to pluripotent stem cells includes over 35 patents issued in the U.S., more than 70 issued in other countries and over 200 applications pending worldwide.
GERN is currently trading at $3.89, up $0.14 or 3.73%, on a volume of 0.20 million shares.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.